Literature DB >> 23410164

Polypharmacology in a single drug: multitarget drugs.

M L Bolognesi1.   

Abstract

Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal.

Mesh:

Substances:

Year:  2013        PMID: 23410164     DOI: 10.2174/0929867311320130004

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  39 in total

Review 1.  Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.

Authors:  Geetha Mathew; M K Unnikrishnan
Journal:  Inflamm Res       Date:  2015-07-18       Impact factor: 4.575

2.  Harnessing Polypharmacology with Medicinal Chemistry.

Authors:  Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

3.  Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Resat Cinar; Bernadette R Gochuico; Malliga R Iyer; Tony Jourdan; Tadafumi Yokoyama; Joshua K Park; Nathan J Coffey; Hadass Pri-Chen; Gergő Szanda; Ziyi Liu; Ken Mackie; William A Gahl; George Kunos
Journal:  JCI Insight       Date:  2017-04-20

Review 4.  Drug combination therapy increases successful drug repositioning.

Authors:  Wei Sun; Philip E Sanderson; Wei Zheng
Journal:  Drug Discov Today       Date:  2016-05-27       Impact factor: 7.851

Review 5.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

Review 6.  Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.

Authors:  Daniela Placha; Josef Jampilek
Journal:  Pharmaceutics       Date:  2021-01-06       Impact factor: 6.321

7.  Chemical Constituents and their Antioxidant, Anti-Inflammatory and Anti-Acetylcholinesterase Activities from Pholidota cantonensis.

Authors:  Liang Liu; Meijia Zou; Kewu Zeng; Xiaoming Ye; Runkun Wang; Wei Wang; Xianwen Zhang
Journal:  Plant Foods Hum Nutr       Date:  2021-02-23       Impact factor: 3.921

8.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

9.  Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.

Authors:  Jagan R Etukala; Xue Y Zhu; Suresh V K Eyunni; Edem K Onyameh; Edward Ofori; Barbara A Bricker; Hye J Kang; Xi-Ping Huang; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-06-04       Impact factor: 3.641

Review 10.  Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors.

Authors:  Hongguang Ma; Boshi Huang; Yan Zhang
Journal:  Drug Discov Today       Date:  2020-07-09       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.